Radiotherapy or Surgery of the Axilla After a Positive Sentinel Node in Breast Cancer: 10-Year Results of the Randomized Controlled EORTC 10981-22023 AMAROS Trial
The Netherlands Cancer Institute · Oncode Institute · +24 more institutions
Abstract
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. PURPOSE The European Organisation for Research and Treatment of Cancer 10981-22023 AMAROS trial evaluated axillary lymph node dissection (ALND) versus axillary radiotherapy (ART) in patients with cT1-2, node-negative breast cancer and a positive sentinel node (SN) biopsy. At 5 years, both…
Citation impact
- FWCI
- 28.70
- Percentile
- 100%
- References
- 12
Authors
26- SASanne A. L. BartelsCorresponding
The Netherlands Cancer Institute, Oncode Institute, European Organisation for Research and Treatment of Cancer
- MDMila Donker
Leiden University Medical Center, The Netherlands Cancer Institute, Oncode Institute
- CPCoralie Poncet
European Organisation for Research and Treatment of Cancer
- NSNicolas Sauvé
European Organisation for Research and Treatment of Cancer
- MEMarieke E. Straver
Medisch Centrum Haaglanden
Topics & keywords
- Medicine
- Breast cancer
- Axillary Lymph Node Dissection
- Axilla
- Sentinel lymph node
- Sentinel node
- Hazard ratio
- Radiation therapy
- Good health and well-being